ClinicalTrials.gg
RecruitingNCT06644846Updated Feb 20, 2026

Spatially Fractionated Radiation Treatment for Gynaecological Cancers

An interventional study of Spatially fractionated radiation therapy in Cervical Cancer, Gynecologic Cancer and Recurrent Cancer, sponsored by Tata Memorial Hospital. Recruiting at 1 site in India. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Tata Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Tata Memorial Hospital.

Planned enrollment
17th of 17
20 · median 316
Started
2024
the only one that year
No phase
10 of 27
2 open now
Registered
21st of 27
by date

Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, this one is the 17th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 21st registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, or all of them as a file.
02

Study summary

This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.

The study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.

Read the detailed description

Patients will be treated with spatially fractionated radiation therapy (SFRT) after EBRT completion to a dose of 25-30 Gy in 5-6 fractions in the primary setting. For patients receiving re-irradiation, 20-25 Gy in 4-5 fractions will be delivered with SFRT, which however may be individualised to match with clinical practice in the re-RT setting. Total EQD2 Gy for organs at risk will be matched to brachytherapy.

The study will be conducted at Tata Memorial Hospital, Mumbai and Advanced Centre for Treatment, Research and Education In Cancer (ACTREC), Navi Mumbai.

03

Conditions studied

  • Cervical Cancer
  • Gynecologic Cancer
  • Recurrent Cancer

Keywords

  • Cervical cancer
  • Cancer
  • Recurrence
  • Spatially fractionated radiotherapy
  • Rapid rod
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with cervical cancer post EBRT, with expected suboptimal brachytherapy dose coverage due to-

    1. Aberrant uterine or pelvic anatomy leading to difficulty in localization of the cervical OS or negotiation of the uterine canal accurately by two independent clinicians in up to two procedures.
    2. Large residual disease at the time of brachytherapy with anticipated suboptimal target coverage either determined in clinic based on pre-brachytherapy imaging or at dose planning (e.g. figure 2).
    3. Very narrow vaginal canal not accommodating even the smallest intracavitary or vaginal cylinder applicators.
  2. Patients with inoperable endometrial cancer not suitable for anaesthesia or have anticipated suboptimal coverage of target volume at brachytherapy as identified on pre-brachytherapy imaging obtained after EBRT.
  3. Patients with large pelvic recurrences after surgery and/or (chemo) radiation, not amenable to surgical salvage or brachytherapy after salvage EBRT due to reasons specified in item 1.
  4. Patients with to anaesthesia for brachytherapy with sufficient risk of on-table or post procedure adverse events.

Exclusion criteria

Exclusion Criteria:

  1. Any pre-existing fistula in bladder or rectum.
  2. Pelvic prosthesis.
  3. Refusal to provide consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    SFRT arm

    This is a single arm phase II study. All patients will receive the planned intervention ie. spatially fractionated radiation therapy using rapid rod technique.

    Radiation: Spatially fractionated radiation therapy

Interventions

  • RadiationSpatially fractionated radiation therapy

    Spatially fractionated" radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of "hot" and "cold" spots within the tumour, thereby sparing nearby organs at risk.

06

What researchers measure

Primary outcomes

  1. In-field control

    To evaluate in-field local control patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT

    Time frame: 1-year

Secondary outcomes

  1. Progression-free and overall survival

    To evaluate progression free and overall survival from the date of end of treatment upto 2 years

    Time frame: 2-years

  2. Late grade 2 or higher genitourinary and gastrointestinal toxicities.

    To evaluate grade 2 or higher genitourinary and gastrointestinal toxicities from the date of end of treatment upto 90 days

    Time frame: > 90 days

  3. To compare SFRT in-silico dose volume parameters with proton beam plans

    To compare dose volume parameters of SFRT plans with proton beam plans, created on the same datasets.

    Time frame: 1-year

  4. To obtain biopsy tissue for translational research before and after SFRT

    Programmed cell death ligand 1 (PD-L-1) expression will be studied

    Time frame: 1-year

  5. To study overall response in reference to PET FDG and Hypoxia imaging at baseline and before SFRT

    To evaluate overall response based on PET-FDG and hypoxia markers at baseline and before SFRT

    Time frame: 1-year

07

Study locations

1 of 1 sites recruiting
  • ACTREC Tata Memorial Centre
    Navi Mumbai, Maharashtra 410210, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 28 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Oct 16, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2029
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644846
Lead sponsor
Tata Memorial Hospital
Responsible party
Supriya Sastri (chopra) (Dr Supriya Sastri, Tata Memorial Hospital) — Principal investigator
First posted
Oct 16, 2024
Start date
Oct 4, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Feb 20, 2026

Study contacts

Supriya Chopra, MD
Contact
supriyasastri@gmail.com
022-68735000 ext. 5113
Ankita Gupta, MD
Contact
ankita19.gupta.ag@gmail.com
9592750011

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion